Inhibitors against the p110d isoform of phosphoinositide-3-OH kinase (PI(3)K) have shown remarkable therapeutic efficacy in some human leukaemias 1, 2 . As p110d is primarily expressed in leukocytes 3 , drugs against p110d have not been considered for the treatment of solid tumours 4 . Here we report that p110d inactivation in mice protects against a broad range of cancers, including non-haematological solid tumours. We demonstrate that p110d inactivation in regulatory T cells unleashes CD8
Inhibitors against the p110d isoform of phosphoinositide-3-OH kinase (PI(3)K) have shown remarkable therapeutic efficacy in some human leukaemias 1, 2 . As p110d is primarily expressed in leukocytes 3 , drugs against p110d have not been considered for the treatment of solid tumours 4 . Here we report that p110d inactivation in mice protects against a broad range of cancers, including non-haematological solid tumours. We demonstrate that p110d inactivation in regulatory T cells unleashes CD8
1 cytotoxic T cells and induces tumour regression. Thus, p110d inhibitors can break tumour-induced immune tolerance and should be considered for wider use in oncology.
PI(3)K p110d D910A (d D910A ) mice, in which endogenous p110d kinase is inactive, present specific immune deficiencies 5, 6 but are not predisposed to cancer. To test whether host p110d activity affects tumour growth, we inoculated weakly immunogenic syngeneic cancer cell lines into d D910A mice. Compared to wild-type mice, d D910A mice were more resistant to B16 melanoma, with reduced tumour incidence and almost abrogated lymph node metastasis in those mice that developed tumours (Fig. 1a) . Growth of Lewis lung carcinoma (LLC) and EL4 thymoma cells was also suppressed in d D910A mice (Fig. 1b, c ). Similar observations were made with luciferase-labelled 4T1 breast cancer cells injected into the mammary fat pad. At euthanization, d
D910A mice showed reduced mass and luciferase activity of the primary 4T1 tumour (Fig. 1d ) and lower metastasis (Fig. 1e) . In wild-type mice, 4T1 tumours were detected by day 10 and grew progressively until day 30, at which point the mice became moribund (Fig. 1f) . In some d D910A mice, 4T1 tumours grew initially, but then started to regress from days 15-20 onwards (Fig. 1f) . Across ten independent experiments, 97% (71/73) of wild-type mice had an observable cancer mass at the end of study, compared to 65% (43/66) of d D910A mice, with a median survival time of 23 and 40 days in wild-type and d D910A mice, respectively (Fig. 1g ). Effective tumour immunity is limited by regulatory T cell (T reg )-mediated immune suppression 7 . d D910A mice show enhanced FOXP3 1 CD4 1 T reg in the thymus but impaired subsequent T reg maintenance and functionality in the periphery 8 . d
D910A T reg also produce less interleukin (IL)-10 and express lower levels of CD38, but show normal expression of most 'T reg -signature' genes, including FOXP3, CD25 (also known as IL2RA), CTLA4 and ICOS 8, 9 . We therefore considered that reduced T reg function in d D910A mice might lead to enhanced tumour resistance. FOXP3
1 CD4 1 T reg in the draining lymph nodes of 4T1 tumour-bearing d D910A mice did not expand as robustly as in wild-type mice (Fig. 2a) ; however, no consistent differences in T reg expansion were observed in the B16 or EL4 tumour models between naive and tumour-bearing mice of either genotype (not shown). To assess T reg function, we carried out adoptive T reg transfer experiments in EL4 tumour-bearing Babraham Research Campus, Cambridge CB22 3AT, UK. 3 Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. 4 Mice with ear tumours (%) (Fig. 2d ). These data demonstrate that p110d inactivation in T reg is both necessary and sufficient to confer tumour resistance. However, these data also revealed a potential negative impact of p110d inhibition on effector T cells, as FOXP3 Data Fig. 1a ). Upon 4T1 inoculation in wild-type mice, the relative numbers of these cells were either enhanced (tumour-draining lymph nodes) or reduced (blood and spleen), but in d D910A mice showed a trend towards expansion (Extended Data Fig. 1a ), indicating that d D910A mice are capable of mounting both CD4 splenocytes from tumour-bearing mice, incubated in vitro with mitomycin C-treated 4T1 cells, generated equivalent cytotoxic activity against 4T1, with no specific lysis of LLC (Fig. 3c ). Compared to wild-type cultures, d D910A cultures contained similar proportions of CD4 and CD8 T-cell subsets (Extended Data Fig. 1b) , with a reduced frequency of activated/memory CD44 high CD4 1 cells (Fig. 3d ) and unaffected frequency of CD44 high CD8 1 cells (Fig. 3d) (Fig. 3e) , with the frequency of IFNc 1 CD8
1 cells even enhanced upon p110d inactivation (Fig. 3e ). Upon inoculation with LLC cells expressing ovalbumin (LLC-OVA), wild-type and d D910A mice generated similar levels of tumour-infiltrating OVAspecific CD8
1 T cells (Fig. 3f) , showing that systemic in vivo inactivation of p110d does not impede the development or recruitment of antigenspecific anti-tumour CD8
1 cells. To test the intrinsic ability of d D910A CD8 T cells to eliminate tumours, we crossed d D910A mice to OT-I transgenic mice, which carry an OVAspecific MHC class I-restricted T-cell receptor transgene. In vitro-generated d D910A OT-I cytotoxic T lymphocytes (CTLs) were less efficient than wild-type OT-I CTLs at EL4-OVA killing ( Fig. 3g ) and produced lower levels of cytotoxic mediators (Extended Data Fig. 1c ). Pharmacological inactivation of p110d during the in vitro CTL expansion of wild-type OT-I cells partially suppressed CTL function, in a manner indistinguishable from genetic inactivation of p110d (Fig. 3g) , whereas p110d blockade during the killing phase itself did not affect CTL function (Fig. 3g ). Despite these in vitro defects in d D910A OT-I CTLs, adoptive transfer of these cells in wild-type mice before challenge with EL4-OVA provided equal cancer protection to inoculation of wild-type OT-I T cells (Fig. 3h) , showing that in vivo CTL responses can remain competent in the absence of CD8 T-cell-intrinsic p110d activity. Taken together, these data indicate that p110d inhibition impairs differentiation of CD8 T cells to become fully competent CTLs; however, fully differentiated CTLs do not seem to require p110d activity to kill target cells and on balance, in the context of reduced T reg function in d D910A mice, can mediate effective anti-tumour activity.
CD4 T cells can also contribute to tumour elimination by promoting the activation of macrophages and natural killer cells or by direct lysis of MHC class II 1 tumour cells 10 . Indeed, CD4 1 T cells with enhanced PI(3)K activity are superior in their capacity to reject tumour growth, probably as a consequence of their increased production of IFN-c 11 .
Conversely, d
D910A OT-II CD4 cells were less effective than wild-type OT-II cells in preventing EL4-OVA tumour growth (Fig. 3h) , consistent with our previous finding that d D910A OT-II T cells produce less IFN-c in vitro and in vivo 12, 13 . Therefore, in the context of an otherwise normal immune system, d
D910A CD4 1 cells show inferior anti-tumour immunity. However, the production of IFN-c by CD4 and CD8 T cells from 4T1 tumourbearing d D910A mice, in which T reg are also defective, appeared to be intact ( Fig. 3e) , suggesting that p110d inhibition can affect the balance between regulatory and effector CD4
1 T cells such that the effector cells prevail in the context of anti-tumour responses.
A salient feature of CD4 and CD8 T cells is the ability to raise a more potent and rapid immune response to subsequent exposure to cognate antigen. Upon surgical removal of 4T1 primary tumours when they had reached 9 mm in diameter and established metastatic foci 14 , wild-type mice all succumbed to regrowth of the primary tumour and metastatic disease. By contrast, .50% of post-surgical d D910A mice showed survival extension beyond 100 days (Fig. 3i) , demonstrating that p110d inhibition can suppress cancer relapse and presumably metastatic cancer after surgery. d D910A mice which had remained tumour-free for .200 days after surgery were cancer-resistant upon rechallenge with a higher 4T1 dose (Fig. 3j) , suggesting that surgical intervention in d D910A mice supports the development of an effective memory anti-tumour response. 
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To assess the potential importance of p110d in myeloid cells in cancer, we tested the impact of p110d inactivation in Rag 2/2 mice. Rag 2/2 mice, which lack mature B and T cells, showed enhanced primary 4T1 tumour size and metastasis (Fig. 4a) (Fig. 4a) and liver (not shown), indicating that p110d inactivation in a non-B/T-cell lineage delays 4T1 tumour progression but is not sufficient to instigate tumour rejection. We next assessed the impact of p110d inactivation on myeloidderived suppressor cells (MDSCs), a heterogeneous population of bone marrow-derived myeloid cells that co-express the CD11b and Gr1 surface markers and which have a prominent role in immune suppression in cancer 15, 16 . Neutrophils are also CD11b 1 Gr1 1 but are thought not to be immune-suppressive 17 . Upon inoculation with 4T1 cells, known to be potent MDSC inducers 16, 17 , CD11b
1 Gr1 high cells accumulated in the spleens of both wild-type and d D910A mice, even before tumours were palpable, and continued to differentially accumulate in both genotypes as tumours grew, correlating with tumour size (Fig. 4b) . The Ly6C and Ly6G surface markers, which are both recognized by the Gr1 antibody, have been used to subdivide MDSCs into two CD11b . Although neutrophils are difficult to differentiate from PMN-MDSCs, here we designated the neutrophil population as Ly6G high cells with intermediate/ high Ly6C expression (Fig. 4c and Extended Data Fig. 2a) . PMN-MDSCs, predominant in 4T1 tumour-bearing wild-type mice (Fig. 4c) , were substantially reduced in d D910A mice, correlating with a relative increase in neutrophils in the latter (Fig. 4c) . Interestingly, the number of PMNMDSCs in spleens from 4T1 tumour-bearing mice correlated with the number of T regs (Fig. 4d) . Depletion of CD8
1 cells in 4T1 tumour-bearing d D910A mice, which led to enhanced tumour growth (Fig. 3a, b) , also led to increased PMN-MDSC numbers and reduced neutrophil numbers (Fig. 4e) . It was therefore difficult to ascertain whether the reduced PMN-MDSC numbers in d D910A mice are a consequence of an intrinsic role for p110d in these cells or an indirect consequence of a reduced tumour burden in d D910A mice (Fig. 4b) . In support of the former, wild-type PMN-MDSCs suppressed T-cell proliferation in vitro, whereas MDSCs from d D910A mice with regressing tumours did not ( Fig. 4f and Extended Data Fig. 2b ). Neutrophils from both genotypes did not suppress T-cell responses (Fig. 4f) . Moreover, splenocytes from tumour-bearing d D910A mice showed reduced in vitro production of transforming growth factorb, vascular endothelial growth factor and IL-6 (Fig. 4g) , each of which can contribute to immune suppression and/or tumour growth 15, 16 . Administration of PI-3065, a small molecule inhibitor with selectivity for p110d (Extended Data Fig. 3a, b and Extended Data Table 1) , also suppressed 4T1 tumour growth and metastasis, to a similar extent as genetic inactivation of p110d, marked by initial tumour progression, followed by tumour regression (Fig. 5a and Extended Data Fig. 3c, d ). Of interest, 4T1 cells do not express detectable levels of p110d (Extended Data Fig. 3e ) and are not growth-inhibited in vitro by PI-3065 (Extended Data Fig. 3f ). Long-term administration of PI-3065 to mice was welltolerated and did not induce weight loss (Extended Data Fig. 3g) .
We next tested the impact of PI-3056 in the LSL.Kras
Pdx
Cretg/1 (or KPC) model of pancreatic ductal adenocarcinoma, which expresses endogenous mutant KRAS G12D and p53 R172H in PDX1 1 pancreatic cells. KPC mice were left to develop palpable disease before treatment with vehicle or PI-3065 was commenced. Under these therapeutic conditions, PI-3065 prolonged survival and reduced the incidence of macroscopic metastases and other disease-associated pathologies (Fig. 5b) . The relative abundance of peripheral T reg in lymph nodes after 7 days 
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of treatment was reduced (Fig. 5c) , correlating with higher levels of CD44 high CD8 1 lymphocytes in the draining lymph nodes (Fig. 5d ) and relatively higher levels of infiltrating CD8
1 T cells in pancreatic lesions 14 days after treatment (Fig. 5e ). These data indicate that therapeutic targeting of p110d can promote immune-mediated elimination of cancer.
Concerns have been raised about inhibiting p110d in cancer as this might impair CTLs and negatively impact on cancer immune surveillance 4, 18 . Our data show that although p110d blockade reduces the effectiveness of CTLs, it also overrides T reg -and probably also MDSC-mediated suppression of anti-tumour immune responses, enabling even weakened CTLs to successfully attack tumours. Thus, p110d is apparently more essential for regulatory rather than effector T-cell responses against cancer cells. In addition, inhibition of the PI(3)K pathway in CD8 T cells may help maintain them in a stem-cell like state 19 with enhanced potential for generating durable anti-tumour responses. Consistent with this notion, d
D910A mice resisted tumour rechallenge following surgical removal of the first tumour. The p110d inhibitor Idelalisib has shown impressive therapeutic impact in chronic lymphocytic leukaemia (CLL) and non-Hodgkin's lymphoma 1, 2 . In CLL, p110d blockade interferes with stroma-derived survival and adhesion signals supporting the tumour cells 4 , but it is unclear if this fully explains the effectiveness of p110d inhibition. Our finding that p110d inhibition can unlock adaptive antitumour responses provides a potential additional mechanism for the efficacy of p110d blockade in CLL, and adds to the emerging rationale for targeting PI(3)K in the tumour stroma 4 , to dampen inflammation (p110c) 20 and angiogenesis (p110a) 21 . Tumour-induced immune suppression constitutes an important barrier for effective anti-tumour immunity and immunotherapy in cancer. Our work suggests that p110d inhibitors, by disrupting the function of T reg and possibly of MDSCs, have the potential to shift the balance from immune tolerance towards effective anti-tumour immunity. This provides a rationale for p110d inhibition both in solid and haematological cancers, possibly as an adjuvant to cancer vaccines, adoptive cell therapy, or other strategies that promote tumour-specific immune responses. 
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METHODS SUMMARY
All animal procedures were in compliance with institutional animal care and use committee guidelines. Details of procedures and reagents are described in Supplementary Information.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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